Study limitation: The study enrolled patients with implantable cardioverter defibrillators for primary prevention, which may limit generalisability to broader HFrEF populations without ICDs | ReachRx
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Study limitation reported by the research below: “The study enrolled patients with implantable cardioverter defibrillators for primary prevention, which may limit generalisability to broader HFrEF populations without ICDs.”
